Purification and properties of recombinant GST-haparinase III and optimizationm of cultivation conditions

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 25, Issue 11, 2009, Pages 1718-1724

  Gao, Xing ^a   Zhao, Jian ^a   Fan, Liqiang ^a   Li, Suxia ^a   Wang, Fujun ^b   Ji, Shengli ^c   Yuan, Qinsheng ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Zhejiang Reachall Pharmaceutical Co Ltd   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Characterization; Flavobacterium heparinum; Glutathione S transferase (GST); Heparinase III; Soluble expression

Indexed keywords

GLUTATHIONE TRANSFERASE; HEPARIN LYASE; HYBRID PROTEIN;

ARTICLE; BIOSYNTHESIS; ENZYMOLOGY; ESCHERICHIA COLI; FLAVOBACTERIUM; GENETICS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; METABOLISM;

ESCHERICHIA COLI; FLAVOBACTERIUM; GLUTATHIONE TRANSFERASE; HEPARIN LYASE; RECOMBINANT FUSION PROTEINS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; FLAVOBACTERIUM; PEDOBACTER HEPARINUS;

EID: 77954796549     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Dietrich CP, Nader HB, Strauss AJ. Structural differences of heparan sulfates according to the tissue and species of origin. Biochem Biophys Res Commun, 1983, 111: 865-871.
2. Kjellen L, and Lindahl U. Proteoglycans: structures and Interactions. Annu Rev Biochem, 1991, 60: 443-475.
3. Lindahl U, Lidholt K, Spillmann DL, et al. More to "heparin" than anticoagulation. Thromb Res, 1994, 75: 1-32.
4. David G. Integral membrane heparan sulfate proteoglycans. FASEB J, 1993, 7: 1023-1030.
5. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev, 1991, 71: 481-539.
6. Wight TN, Kinsella MG, Qwarnstromn EE. The role of proteoglycans in cell adhesion, migration and proliferation Curr Opin Cell Biol, 1992, 4: 793-801.
7. Taipale J, Keski-Oji J. Growth factors in the extracellular matrix. FASEB J, 1997, 11: 51-59.
8. Guimond S, Maccarana M, Olwin BB, et al. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem, 1993, 268: 23906-23914.
9. Lyon M, Deakin JA, Mizuno K, et al. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem, 1994, 269: 11216-11223.
10. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res, 1996, 37: 693-707.
11. Rapraeger AC. The coordinated regulation of heparan sulfate, syndecans and cell behavior. Curr Opin Cell Biol, 1993, 5: 844-853.
12. Nakajima M, Iramura T, Ferrante ND, et al. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem, 1984, 259: 2283-2290.
13. Linker A, Hovingh P. The uses of degradative enzymes as tools for identification and structural analysis of glycosaminoglycans. Fed Proc, 1977, 36: 43-46.
14. Dietrich CP, Silva ME, Michelacci YM. Sequential degradation of heparin in Flavobacterium heparinum. J Biol Chem, 1973, 248: 6408-6415.
15. Hutt ED, Kingdom HS. Use of heparinase to eliminate heparin inhibition in routine coagulation assays. J Lab Clin Med, 1972, 79:1027-1034.
16. Kanwar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. Proc Natl Acad Sci USA, 1979, 76:1303-1307.
17. Lindahl U, Backstrom G, Hook M, et al. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA, 1979, 76: 3198-3202.
18. Linhardt RJ, Grant A, Cooney CL, et al. Differential anticoagulant activity of heparin fragments prepared using microbial heparinase. J Biol Chem, 1982, 257: 7310-7313.
19. Folkman J, Langer R, Linhardt RJ, et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science, 1983, 221: 719-725.
20. Langer R, Linhardt RJ, Hoffberg S, et al. An enzymatic system for removing heparin in extracorporeal therapy. Science, 1982, 217: 261-263.
21. Ototani N, Kikuchi M, Yosizawa Z. Purification of heparinase and heparitinase by affinity chromatography on glycosaminoglycan-bound AH-Sepharose 4B. Carbohydr Res, 1981, 88: 291-303.
22. Su H, Blain F, Musil RA, et al. Isolation and Expression in Escherichia coli of hepB and hepC, genes coding for the glycosaminoglycan-degrading enzymes heparinase II and heparinase III, respectively, from Flavobacterium heparinum. Appl Environ Microbiol, 1996, 62: 2723-2734.
23. Godavarti R, Davis M, Cooney C, et al. Heparinase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. Biochem Biophys Res Commun, 1996, 225: 751-758.
24. 2 as activity stabilizer on purification of heparinase I from Flavobacterium heparinum. J Chromatogr B, 2006, 843: 209-215.
25. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Riochem, 1976, 72: 248-254.
26. Sasisekharan R, Bulmer M, Moremen KW, et al. Cloning and expression of heparinase I gene from Flavobacterium heparinum. Proc Natl Acad Sci USA, 1993, 90: 3660-3664.
27. Lohse DL, Linhardt RJ. Purification and characterization of heparin lyases from Flavobacterium heparinum. J Biol Chem, 1992, 267: 24347-24355.
28. Ahsan A, Jeske W, Mardiguian W, et al. Feasibility study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins. J Pharm Sci, 1994, 83: 197-201.